Minerva Surgical, Inc. engages in the research, development, manufacture, and commercialization of invasive solutions for uterine healthcare needs of women. The company is headquartered in Santa Clara, California and currently employs 174 full-time employees. The company went IPO on 2021-10-22. The firm is engaged in manufacturing and distribution of invasive gynecologic technologies. The firm is focused on improving women's health and quality of life by providing access to minimally invasive, technologically advanced, and innovative solutions for early detection, treatment, and management of uterine conditions. The company delivers devices that treat the root causes of Abnormal Uterine Bleeding (AUB) in both the normal and irregular shaped uterus. The firm's products include Minerva ES Endometrial Ablation System (Minerva ES), Genesys HTA Endometrial Ablation System (Genesys HTA), Symphion Operative Hysteroscopy System (Symphion), Resectr Tissue Resection Device (Resectr), and Disposable Hysteroscope. Minerva ES is an endometrial ablation device that utilizes its PlasmaSense technology. Symphion System is designed to transform the way you see and remove uterine fibroids and polyps.
